Retinal vein occlusion (RVO) is a prevalent, vision-threatening disease, of which macular edema is a common complication. Standard treatment for RVO-associated macular edema involves intravitreal treatment with anti–vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab, bevacizumab, or aflibercept. Despite success with these agents in clinical trials, anti-VEGF agents may be administered less frequently in clinical practice than in studies.
Retinal vein occlusion (RVO) is a prevalent, vision-threatening disease, of which macular edema is a common complication. Standard treatment for RVO-associated macular edema involves intravitreal treatment with anti—vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab, bevacizumab, or aflibercept. Despite success with these agents in clinical trials, anti-VEGF agents may be administered less frequently in clinical practice than in studies.
Researchers sought to evaluate the efficacy, safety, and injection frequency of anti-VEGF drugs in treating macular edema secondary to RVO in clinical practice, and used a multicenter, retrospective, open-label chart review of 165 patients 18 years and older who received at least 3 intravitreal injections of anti-VEGF from August 2013 to September 2014.
A total of 117 patients had 1 year or more of follow-up after anti-VEGF treatment, and 40 (24.2%) continued to receive anti-VEGF injections and had data available through year 2. Seventeen (10.3%) continued therapy and had data available through year 3.
A total of 1641 anti-VEGF injections were administered, 842 (51.3%) of which were ranibizumab, 724 (41.1%) of which were bevacizumab, and 75 (4.6%) of which were aflibercept. Most patients received repeated injections of 1 agent, but 33.3% (n = 55) of patients switched agents at least 1 time during the study period.
In controlled clinical trials conducted for its approval, ranibizumab was administered monthly for 6 months and as needed through 1 year. By contrast, in this study, patients received a mean of 7.1 (range, 1-15) anti-VEGF injections in year 1, 5.4 (range, 1-13) in year 2, and 5.9 (range, 1-11) in year 3. The mean interval between injections ranged from 1.1 to 1.6 months across the first 16 injections.
The primary end point of combined visual and anatomic response (measured as best-corrected visual acuity of 20/40 or better and central retinal thickness of 250 mcm or less on time-domain optical coherence tomography or 300 mcm or less on spectral-domain optical coherence tomography at the same visit) was achieved by just 20.0% to 36.7% of patients after the first 16 injections.
“In this real-world study, a mean of [5] to [7] anti-VEGF injections was administered yearly, and the response to anti-VEGF therapy was suboptimal in many patients,” write the authors. “More frequent injections may improve outcomes, but some patients do not achieve a dry macula even with monthly injections.”
Reference
Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophtalmol. 2018;12:621-629. doi: 10.2147/OPTH.S163859.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.